212 related articles for article (PubMed ID: 25858813)
1. Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.
Cereda V; Formica V; Menghi A; Pellicori S; Roselli M
Expert Opin Investig Drugs; 2015; 24(7):929-47. PubMed ID: 25858813
[TBL] [Abstract][Full Text] [Related]
2. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
3. Targeting kallikrein-related peptidases in prostate cancer.
Mavridis K; Avgeris M; Scorilas A
Expert Opin Ther Targets; 2014 Apr; 18(4):365-83. PubMed ID: 24571737
[TBL] [Abstract][Full Text] [Related]
4. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
5. A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.
Lovell S; Zhang L; Kryza T; Neodo A; Bock N; De Vita E; Williams ED; Engelsberger E; Xu C; Bakker AT; Maneiro M; Tanaka RJ; Bevan CL; Clements JA; Tate EW
J Am Chem Soc; 2021 Jun; 143(23):8911-8924. PubMed ID: 34085829
[TBL] [Abstract][Full Text] [Related]
6. The kallikrein-related peptidase family: Dysregulation and functions during cancer progression.
Kryza T; Silva ML; Loessner D; Heuzé-Vourc'h N; Clements JA
Biochimie; 2016 Mar; 122():283-99. PubMed ID: 26343558
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there.
Pasic MD; Olkhov E; Bapat B; Yousef GM
Biol Chem; 2012 Apr; 393(5):319-30. PubMed ID: 22505515
[TBL] [Abstract][Full Text] [Related]
8. Proteomic and other analyses to determine the functional consequences of deregulated kallikrein-related peptidase (KLK) expression in prostate and ovarian cancer.
Fuhrman-Luck RA; Silva ML; Dong Y; Irving-Rodgers H; Stoll T; Hastie ML; Loessner D; Gorman JJ; Clements JA
Proteomics Clin Appl; 2014 Jun; 8(5-6):403-15. PubMed ID: 24535680
[TBL] [Abstract][Full Text] [Related]
9. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
10. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer.
White NM; Youssef YM; Fendler A; Stephan C; Jung K; Yousef GM
Biol Chem; 2012 Apr; 393(5):379-89. PubMed ID: 22505520
[TBL] [Abstract][Full Text] [Related]
11. Predictions for the future of kallikrein-related peptidases in molecular diagnostics.
Scorilas A; Mavridis K
Expert Rev Mol Diagn; 2014 Jul; 14(6):713-22. PubMed ID: 24927162
[TBL] [Abstract][Full Text] [Related]
12. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2012 Apr; 393(5):301-17. PubMed ID: 22505514
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometry based proteomics analyses in kallikrein-related peptidase research: implications for cancer research and therapy.
Silva LM; Clements JA
Expert Rev Proteomics; 2017 Dec; 14(12):1119-1130. PubMed ID: 29025353
[TBL] [Abstract][Full Text] [Related]
15. Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer.
Loessner D; Goettig P; Preis S; Felber J; Bronger H; Clements JA; Dorn J; Magdolen V
Expert Opin Ther Targets; 2018 Sep; 22(9):745-763. PubMed ID: 30114962
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of kallikrein-related peptidases (KLK) in urogenital malignancies.
Dorn J; Bayani J; Yousef GM; Yang F; Magdolen V; Kiechle M; Diamandis EP; Schmitt M
Thromb Haemost; 2013 Sep; 110(3):408-22. PubMed ID: 23765253
[TBL] [Abstract][Full Text] [Related]
17. KLK-targeted Therapies for Prostate Cancer.
Hannu K; Johanna M; Ulf-Håkan S
EJIFCC; 2014 Sep; 25(2):207-18. PubMed ID: 27683469
[TBL] [Abstract][Full Text] [Related]
18. Human kallikrein-related peptidase 12: antibody generation and immunohistochemical localization in prostatic tissues.
Memari N; Diamandis EP; Earle T; Campbell A; Van Dekken H; Van der Kwast TH
Prostate; 2007 Sep; 67(13):1465-74. PubMed ID: 17654496
[TBL] [Abstract][Full Text] [Related]
19. Activation profiles and regulatory cascades of the human kallikrein-related peptidases.
Yoon H; Laxmikanthan G; Lee J; Blaber SI; Rodriguez A; Kogot JM; Scarisbrick IA; Blaber M
J Biol Chem; 2007 Nov; 282(44):31852-64. PubMed ID: 17823117
[TBL] [Abstract][Full Text] [Related]
20. Drug design strategies for the treatment of prostate cancer.
Lauer RC; Friend SC; Rietz C; Pasqualini R; Arap W
Expert Opin Drug Discov; 2015 Jan; 10(1):81-90. PubMed ID: 25366417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
